Evidence map›Paper›PMID 34519923›Full record

ArticleFamilial cancer2022

A de novo pathogenic variant in the MSH6 gene in a 52 years-old woman.

Elise Pierre-Noël, Fabrice Airaud, Estelle Cauchin, Céline Garrec, Ingrid Ricordeau, Clémence Michon, Olivier Kerdraon, Stéphane Bezieau, Caroline Abadie

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Familial cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elise Pierre-NoëlService de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, 9 quai Moncousu, 44093, Nantes, France.
Fabrice AiraudService de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, 9 quai Moncousu, 44093, Nantes, France.
Estelle CauchinCentre Hospitalier Universitaire de Nantes, Institut des maladies de l'appareil digestif, 1 place Alexis-Ricordeau, 44093, Nantes, France.
Céline GarrecService de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, 9 quai Moncousu, 44093, Nantes, France.
Ingrid RicordeauService de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, 9 quai Moncousu, 44093, Nantes, France.
Clémence MichonInstitut de Cancérologie de l'Ouest, laboratoire d'Oncopharmacologie et pharmacogénétique, 15 rue André Boquel, 49055, Angers, France.
Olivier KerdraonDépartement de pathologie tissulaire et moléculaire, Institut de Cancérologie de l'Ouest, Boulevard Professeur Jacques Monod, 44800, Saint-Herblain, France.
Stéphane BezieauService de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, 9 quai Moncousu, 44093, Nantes, France.
Caroline AbadieInstitut de Cancérologie de l'Ouest, Unité d'Oncogénétique, Boulevard Professeur Jacques Monod, 44800, Saint- Herblain, France. caroline.abadie@ico.unicancer.fr.ORCID http://orcid.org/0000-0002-1425-6926
Centre Hospitalier Universitaire de Nantes · FRInstitut de Cancérologie de l'Ouest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lynch syndrome (LS) is a condition which predisposes individuals primarily to early-onset colorectal and endometrial cancer. LS is characterized by a germline pathogenic variant in one of the MMR (MisMatch Repair) gene, inducing a phenotype of microsatellite instability in the tumor, which may be associated with a loss of expression of MMR proteins detected by standard immunohistochemistry on tumor tissue. Most of the time, LS is inherited from a parent in whom the condition may not be known due to incomplete penetrance, but de novo pathogenic variant is a rare occurrence. Here, we describe the case of a 52-year-old woman with no family history of LS, referred to the genetics department for colorectal cancer at the age of 50. Genetic analysis revealed a de novo germline pathogenic variant in the MSH6 gene. To date, this case is only the second report of a de novo pathogenic variant in the MSH6 gene in Lynch syndrome. De novo mutations have been extensively studied over the past years, but little is known about their origin and mechanism of occurrence in MMR genes. However, knowledge of mutation status allows better cancer risk management for the patient and an appropriate genetic testing and counseling for her family.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairFemaleGerm-Line MutationHumansMicrosatellite InstabilityMutL Protein Homolog 1MutS Homolog 2 ProteinMutL Protein Homolog 1MutS Homolog 2 Proteinde novo mutations (DNMs)Genetic fingerprints.LynchMismatch repair genes (MMR genes)MLH1MosaicismMSH2MSH6

Identifiers

PMID34519923
OpenAlexW3199367400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.